IB1007

IB1007 is a preclinical investigational biologic originally developed by Inspiration Biopharmaceuticals and later included among assets sold by Ipsen/Inspiration to Cangene, described only as a product candidate alongside the recombinant factor IX therapy IB1001 for hemophilia and other bleeding disorders. Publicly available information identifies IB1007 as a distinct clotting-factor–related hemostatic agent but does not disclose its exact molecular identity, target coagulation factor, or detailed mechanism of action. It has not entered clinical trials or obtained regulatory approvals, and no detailed data on its pharmacology, route of administration, or specific indications beyond the general context of bleeding disorders are available.